193 related articles for article (PubMed ID: 22102553)
1. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
Rabin KR; Gramatges MM; Borowitz MJ; Palla SL; Shi X; Margolin JF; Zweidler-McKay PA
Pediatr Blood Cancer; 2012 Sep; 59(3):468-74. PubMed ID: 22102553
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.
Rubnitz JE; Campbell P; Zhou Y; Sandlund JT; Jeha S; Ribeiro RC; Inaba H; Bhojwani D; Relling MV; Howard SC; Campana D; Pui CH
Cancer; 2013 Jun; 119(11):2061-6. PubMed ID: 23456849
[TBL] [Abstract][Full Text] [Related]
3. Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.
Farkas T; Müller J; Erdelyi DJ; Csoka M; Kovacs GT
Pathol Oncol Res; 2017 Oct; 23(4):889-897. PubMed ID: 28138921
[TBL] [Abstract][Full Text] [Related]
4. Absolute Lymphocyte Count Recovery Independently Predicts Outcome in Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Care Cancer Center of a Developing Country.
Gupta A; Kapoor G; Jain S; Bajpai R
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e143-9. PubMed ID: 26201035
[TBL] [Abstract][Full Text] [Related]
5. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
7. Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia.
Pushpam D; Rajput N; Chopra A; Vishnubhatla S; Kumari M; Kumar R; Bakhshi S
Pediatr Hematol Oncol; 2019 Apr; 36(3):138-150. PubMed ID: 31046540
[TBL] [Abstract][Full Text] [Related]
8. Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia.
Hirase S; Hasegawa D; Takahashi H; Moriwaki K; Saito A; Kozaki A; Ishida T; Yanai T; Kawasaki K; Yamamoto N; Kubokawa I; Mori T; Hayakawa A; Nishimura N; Nishio H; Iijima K; Kosaka Y
Int J Hematol; 2015 Nov; 102(5):594-601. PubMed ID: 26440971
[TBL] [Abstract][Full Text] [Related]
9. The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood B-lineage acute lymphoblastic leukemia.
Cheng Y; Luo Z; Yang S; Jia M; Zhao H; Xu W; Tang Y
Leuk Res; 2015 Feb; 39(2):144-50. PubMed ID: 25542697
[TBL] [Abstract][Full Text] [Related]
10. Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
Chen X; Liu C; Zhang A; Wu W; Liu L; Lan Y; Yi M; Zhang L; Ruan M; Chang L; Zhang L; Zou Y; Chen Y; Yang W; Guo Y; Chen X; Zhang Y; Zhu X
Ann Hematol; 2021 Sep; 100(9):2269-2277. PubMed ID: 33443592
[TBL] [Abstract][Full Text] [Related]
11. Absolute lymphocyte count is associated with minimal residual disease level in childhood B-cell precursor acute lymphoblastic leukemia.
Shen HQ; Feng JH; Tang YM; Song H; Yang SL; Shi SW; Xu WQ
Leuk Res; 2013 Jun; 37(6):671-4. PubMed ID: 23453285
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
13. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
16. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.
Sun D; Elson P; Liedtke M; Medeiros BC; Earl M; Alizadeh A; Bates J; Sekeres MA; Coutre S; Kalaycio M; Sobecks R; Copelan E; Advani AS
Am J Hematol; 2012 Oct; 87(10):957-60. PubMed ID: 22729847
[TBL] [Abstract][Full Text] [Related]
17. Absolute Lymphocyte Count at the End of Induction as a Surrogate Marker for Minimal Residual Disease in T-cell Acute Lymphoblastic Leukemia.
Pushpam D; Chopra A; Sreenivas V; Kumar R; Bakhshi S
Indian Pediatr; 2019 May; 56(5):381-383. PubMed ID: 30898988
[TBL] [Abstract][Full Text] [Related]
18. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
